AU2002339603A1 - Replicons derived from positive strand rna virus genomes useful for the production of heterologous proteins - Google Patents

Replicons derived from positive strand rna virus genomes useful for the production of heterologous proteins

Info

Publication number
AU2002339603A1
AU2002339603A1 AU2002339603A AU2002339603A AU2002339603A1 AU 2002339603 A1 AU2002339603 A1 AU 2002339603A1 AU 2002339603 A AU2002339603 A AU 2002339603A AU 2002339603 A AU2002339603 A AU 2002339603A AU 2002339603 A1 AU2002339603 A1 AU 2002339603A1
Authority
AU
Australia
Prior art keywords
production
rna virus
strand rna
heterologous proteins
positive strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002339603A
Other languages
English (en)
Inventor
Nicolas Escriou
Sylvie Gerbaud
Sylvie Van Der Werf
Marco Vignuzzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Publication of AU2002339603A1 publication Critical patent/AU2002339603A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32211—Cardiovirus, e.g. encephalomyocarditis virus
    • C12N2770/32241—Use of virus, viral particle or viral elements as a vector
    • C12N2770/32243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2002339603A 2001-05-23 2002-05-23 Replicons derived from positive strand rna virus genomes useful for the production of heterologous proteins Abandoned AU2002339603A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29251501P 2001-05-23 2001-05-23
US60/292,515 2001-05-23
PCT/IB2002/002810 WO2002095023A2 (en) 2001-05-23 2002-05-23 Replicons derived from positive strand rna virus genomes useful for the production of heterologous proteins

Publications (1)

Publication Number Publication Date
AU2002339603A1 true AU2002339603A1 (en) 2002-12-03

Family

ID=23124993

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002339603A Abandoned AU2002339603A1 (en) 2001-05-23 2002-05-23 Replicons derived from positive strand rna virus genomes useful for the production of heterologous proteins

Country Status (8)

Country Link
US (2) US20030077251A1 (enExample)
EP (1) EP1390517A2 (enExample)
JP (1) JP2005508610A (enExample)
KR (1) KR20040007567A (enExample)
CN (1) CN1575339A (enExample)
AU (1) AU2002339603A1 (enExample)
CA (1) CA2443258A1 (enExample)
WO (1) WO2002095023A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05012542A (es) 2003-06-05 2006-02-08 Wyeth Corp Composiciones inmunogenicas que comprenden vectores de replicon del virus de la encefalitis equina venezolana y antigenos de la proteina del paramixovirus.
KR100788894B1 (ko) 2005-12-09 2007-12-27 한국전자통신연구원 확대된 서비스 영역을 제공하는 직교 주파수 분할 다중방식의 무선 랜 송수신 시스템 및 그 방법
WO2008103755A1 (en) * 2007-02-20 2008-08-28 Mayo Foundation For Medical Education And Research Treating cancer with viral nucleic acid
US9909192B2 (en) * 2007-06-01 2018-03-06 Universidad De Barcelona Control for virus detection assays based on reverse-transcription polymerase chain reaction
EP2130912A1 (en) * 2008-06-04 2009-12-09 Institut für Viruskrankeiten und Immunprophylaxe Pestivirus replicons providing an RNA-based viral vector system
ES2543222T3 (es) * 2008-09-24 2015-08-17 Ribomic Inc. Aptámero para NGF y uso del mismo
PL2590676T3 (pl) 2010-07-06 2017-02-28 Glaxosmithkline Biologicals Sa Wirionopodobne cząstki dostarczające dla autoreplikujących się cząsteczek rna
EP2591114B1 (en) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisation of large mammals with low doses of rna
DK3243526T3 (da) 2010-07-06 2020-02-17 Glaxosmithkline Biologicals Sa Levering af rna til at udløse flere immunsignalveje
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
BR112013000244A2 (pt) 2010-07-06 2016-05-17 Novartis Ag lipossomas com lipídeos apresentando pka vantajoso para administração de rna
MX341989B (es) 2010-08-31 2016-09-09 Novartis Ag * Liposomas pequeños para el suministro de arn que codifica el inmunogeno.
RS63315B1 (sr) 2010-08-31 2022-07-29 Glaxosmithkline Biologicals Sa Pegilovani lipozomi za isporuku rnk koja kodira imunogen
CA2814386C (en) 2010-10-11 2019-08-20 Novartis Ag Antigen delivery platforms
CA3198966A1 (en) 2011-06-08 2012-12-13 Translate Bio, Inc. Cleavable lipids
US20140206753A1 (en) 2011-06-08 2014-07-24 Shire Human Genetic Therapies, Inc. Lipid nanoparticle compositions and methods for mrna delivery
CA2840989A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
EP4115875A1 (en) * 2011-07-06 2023-01-11 GlaxoSmithKline Biologicals S.A. Liposomes having useful n:p ratio for delivery of rna molecules
KR20230019450A (ko) * 2020-05-29 2023-02-08 온코루스, 인크. 캡슐화된 rna 레플리콘 및 사용 방법
CN114231562A (zh) * 2021-12-15 2022-03-25 中国科学院武汉病毒研究所 一种表达荧光素酶基因的淋巴脉络丛脑膜炎病毒及其构建方法和应用
CN114317563B (zh) * 2021-12-17 2023-09-05 华南理工大学 提高基因表达的rna复制子及其应用
CN117070464A (zh) * 2022-05-16 2023-11-17 上海行深生物科技有限公司 蛋白包裹自复制rna及其制备方法
WO2024225374A1 (ja) * 2023-04-25 2024-10-31 慎治 小笠原 インフルエンザウイルスのＲｄＲｐによるｖＲＮＡの転写及び／又は複製を制御する方法、並びにその利用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9125896D0 (en) * 1991-12-05 1992-02-05 Almond Jeffrey W Bicistronic viruses
WO1994029472A2 (en) * 1993-06-03 1994-12-22 Institut Pasteur Mengovirus as a vector for expression of foreign polypeptides
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow

Also Published As

Publication number Publication date
KR20040007567A (ko) 2004-01-24
WO2002095023A2 (en) 2002-11-28
CN1575339A (zh) 2005-02-02
JP2005508610A (ja) 2005-04-07
US20050118566A1 (en) 2005-06-02
WO2002095023A3 (en) 2003-05-08
US20030077251A1 (en) 2003-04-24
CA2443258A1 (en) 2002-11-28
EP1390517A2 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
AU2002339603A1 (en) Replicons derived from positive strand rna virus genomes useful for the production of heterologous proteins
AU2002305204A1 (en) Ceramic blade and production method therefor
AU2002360820A1 (en) Compositions for dna mediated gene silencing
AU2002310321A1 (en) Compositions and methods for high-level, large-scale production of recombinant proteins
AU2002353310A1 (en) Method for the preparation of nucleic acids
AU2002312431A1 (en) Novel process for preparing rac-bicalutamide and its intermediates
AU2002300166A1 (en) Process for the Preparation of Peptides
AU2003205169A1 (en) Viral vaccine production method
AU2002300655A1 (en) Process for purifying sand
AU2002310296A1 (en) Rna purification methods
AU2002257890A1 (en) Method for replicating the hepatitis C virus
HK1061569A (en) Replicons derived from positive strand rna virus genomes useful for the production of heterologous proteins
AU2001256675A1 (en) Method of preparing virus vector
AU2002254529A1 (en) Nucleic acids for transgene expression
AU2002329441A1 (en) Process for the preparation of 3 - isochromanone
AU2002310969A1 (en) Reporter virus comprising heterologous envelope proteins
AU2002342858A1 (en) Human high-affinity antibody fragments for essential proteins of the hepatitis-c virus
AU2002358085A1 (en) Process for the preparation of 4-methyl-7-aminoquinolones
AU2002318185A1 (en) Process for the preparation of paroxetine substantially free of alkoxy impurities
AU2002324291A1 (en) Process for the preparation of beta-ionylideneacetaldehyde
GB0111442D0 (en) Method for preparing recombinant virus
AU2002317419A1 (en) Process for the preparation of acitretin
GB0121084D0 (en) Improved productivity of heterologous gene expression
AUPR339101A0 (en) Methods for the production of proteins
HK1064705A (en) Compositions and methods for high-level, large-scale production of recombinant proteins

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase